new Delhi. The Russian government has sought India’s help in the manufacture of the Sputnik-5 vaccine. Along with this, Russia has also called for help from India in the Phase III trial of the vaccine. A top official gave this information on Tuesday. Russia has released the first batch of Corona vaccine ‘Sputnik-5’ to its citizens. This vaccine has been developed by the Gamalaya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), which was registered on 11 August.
NITI Aayog member Dr. V.K. Paul said that the government’s eyes are on the Russian vaccine. Paul said, “The vaccine made by Russia is under consideration. The Russian government has approached the government and asked for help on two things. First, the large scale manufacture of the vaccine with the help of the country’s network companies. Second. – Phase 3 trial of vaccine in India. ”
Dr. Paul said, “The Government of India attaches great importance to this proposal of partnership with a special friend.”
Describing it as a win-win situation for India, Paul said, “India can manufacture a large and significant amount of the vaccine that is good for Russia and India, and a specific portion of that quantity should also be provided to the other world.” Could. ”
The NITI Aayog member said, “We are working in partnership with this vaccine candidate to build a spirit of science and humanity for the manufacturing ring, trial and regulatory process.”
He said that outreach has been expanded for many companies in India for this and four of them have already come forward. Paul said that others are in discussion with their Russian counterpart and the government is facilitating the process of how the connection can be made.
Explain that there are already three vaccine trials in India. In these, the registration of people for the phase two trial of Bharat Biotech has started from Tuesday. While the phase-two trial of Cadila-Zydus is already underway. The third vaccine is from Oxford University, which is going to build the Serum Institute in India. The trial of its third phase will begin next month at 17 locations, in which 1,600 people will be vaccinated. This vaccine is already undergoing trials on thousands of people in the US and Brazil.
Leave a Reply